ライフサイエンスコーパス: gastrectomy

1 edures (aortic and mitral valve replacement, gastrectomy).

2 ic procedure (eg, a gastric bypass or sleeve gastrectomy).

3 ble gastric banding, and laparoscopic sleeve gastrectomy.

4 age, 12% transhiatal, and 19% extended total gastrectomy.

5 rapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

6 er distal (DG), proximal (PG), or total (TG) gastrectomy.

7 ains disease-free 36 months after completion gastrectomy.

8 to those of other patients undergoing total gastrectomy.

9 pproach for limited, subtotal and even total gastrectomy.

10 ia, age, chronic heart failure, and subtotal gastrectomy.

11 NI, and resection other than distal subtotal gastrectomy.

12 e risk for Barrett's esophagus after partial gastrectomy.

13 enetration; 18 had undergone vagotomy and 11 gastrectomy.

14 proximal gastrectomy and 33 underwent total gastrectomy.

15 d a distal gastrectomy and 71 required total gastrectomy.

16 eraged 29 years since their original partial gastrectomy.

17 ting a recommendation for prophylactic total gastrectomy.

18 rapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

19 ase after Roux-en-Y gastric bypass or sleeve gastrectomy.

20 previous HER2-targeted therapy, and previous gastrectomy.

21 alized costs following curative-intent total gastrectomy.

22 , 22 to 30) among those who underwent sleeve gastrectomy.

23 stric band placement, or laparoscopic sleeve gastrectomy.

24 robot-assisted kidney transplant and sleeve gastrectomy.

25 anding, and 60% (95% CI, 51-70) after sleeve gastrectomy.

26 orated gastric ulcers, necessitating a wedge gastrectomy.

27 with curative intent either by laparoscopic gastrectomy (1,477 patients) or open gastrectomy (1,499

28 oscopic gastrectomy (1,477 patients) or open gastrectomy (1,499 patients) between April 1998 and Dece

29 hich included 74% gastric bypass, 15% sleeve gastrectomy, 10% adjustable gastric banding, and 1% othe

30 rate analyses of 64 patients with Billroth-1 gastrectomy, 105 patients with Billroth-2 gastrectomy, a

31 nterval [CI], 3.2%-4.0%), followed by sleeve gastrectomy (2.2%; 95% CI, 1.2%-3.2%), and laparoscopic

32 residents (mastectomy 6.5%; colectomy 22.8%; gastrectomy 23.4%; antireflux procedures 23.4%; pancreat

33 bypass (80-90 min operative time) and sleeve gastrectomy (30-45 min operative time), which, to a high

34 g (n=1053), gastric bypass (795), and sleeve gastrectomy (317), with two procedures undefined.

35 sewing of ulcer (7.6% vs. 7.4%), less use of gastrectomy (4.4% vs. 2.1%, P < 0.001), and less use of

36 Hispanics were more likely to require total gastrectomy (51%) compared with whites (38%), African Am

37 e, with the most dramatic increases seen for gastrectomy (54%), pancreatectomy (31%), and thyroidecto

38 Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater in

39 gastric bypass (161 participants) or sleeve gastrectomy (67) were included in the analysis.

40 n, esophagectomy, colectomy, pancreatectomy, gastrectomy, abdominal aortic aneurysm repair, hip repla

41 43.1; 95% CI, 19.7-94.5), followed by sleeve gastrectomy (adjusted RR, 16.6; 95% CI, 4.7-58.4) and ga

42 cisions regarding the efficacy of completion gastrectomy after discovery of carcinoma.

43 on group included 865 patients who underwent gastrectomy alone and 268 patients who underwent gastrec

44 For gastrectomies and colectomies, risk-adjusted mortality i

45 MATERIAL/Records of 104 consecutive total gastrectomies and distal esophagectomies were analysed.

46 omesenteric vein thrombosis, 16 after sleeve gastrectomy and 1 following adjustable gastric banding.

47 Of these, 65 underwent proximal gastrectomy and 33 underwent total gastrectomy.

48 For DGC, 258 required a distal gastrectomy and 71 required total gastrectomy.

49 d obesity in the United States toward sleeve gastrectomy and away from the adjustable gastric band.

50 s, the patient worsened and underwent distal gastrectomy and cholecystectomy that included removing t

51 The longitudinal gastrectomy and duodenal switch procedure as performed f

52 odes examined or operative mortality between gastrectomy and esophagectomy.

53 ctomy and gastrojejunostomy (n = 5) or total gastrectomy and esophagojejunostomy (n = 4).

54 oduodenectomy (with the addition of a distal gastrectomy and extended retroperitoneal lymphadenectomy

55 Patients were treated with subtotal gastrectomy and gastrojejunostomy (n = 5) or total gastr

56 ty involves a 75% subtotal greater curvature gastrectomy and long limb suprapapillary Roux-en-Y duode

57 Of the bariatric surgery models, sleeve gastrectomy and mRYGB had higher success rates and lower

58 three had nodal infiltration requiring total gastrectomy and one an adenocarcinoma) and iron-deficien

59 re, we showed that bariatric surgery (sleeve gastrectomy and proximal and distal RYGB) dynamically af

60 of QOL impairment with their patients before gastrectomy and reassure them that most symptoms resolve

61 fit is derived from the addition of a distal gastrectomy and retroperitoneal lymphadenectomy to a pyl

62 duodenectomy (standard resection plus distal gastrectomy and retroperitoneal lymphadenectomy).

63 d) pancreaticoduodenectomy (including distal gastrectomy and retroperitoneal lymphadenectomy).

64 duodenectomy (standard resection plus distal gastrectomy and retroperitoneal lymphadenectomy).

65 salvage of antibiotic failures is required, gastrectomy and/or chemotherapy have frequently been use

66 hundred seventy-two esophagectomies, 12,622 gastrectomies, and 9116 pancreatectomies were examined.

67 d from 2 to 29 esophagectomies, from 1 to 14 gastrectomies, and from 2 to 31 pancreatectomies per sur

68 We retrieved data on esophagectomies, gastrectomies, and pancreatectomies for cancer from the

69 paroscopic adjustable gastric band, 0 sleeve gastrectomy, and 0.14% (95% CI, 0.08%-0.25%) of the gast

70 -1 gastrectomy, 105 patients with Billroth-2 gastrectomy, and 33 patients with vagotomy and pyloropla

71 ic Roux-en-Y gastric bypass, vertical sleeve gastrectomy, and adjustable gastric banding were perform

72 -19%, and -5% in the gastric-bypass, sleeve-gastrectomy, and medical-therapy groups, respectively),

73 Each additional case of esophagectomy, gastrectomy, and pancreatectomy would reduce 30-day mort

74 Surgical management (gastric banding, sleeve gastrectomy, and Roux-en Y gastric bypass) can produce r

75 gastric banding for morbid obesity, partial gastrectomy, and various other procedures.

76 setting: common channel 75 to 125 cm, sleeve gastrectomy (approximately 100 mL gastric pouch), closed

77 afety, and durability of laparoscopic sleeve gastrectomy as a definitive therapeutic option for sever

78 essive regimes may be prescribed after total gastrectomy as long as their limitations are noted.

79 e prospectively enrolled patients undergoing gastrectomy at our institution between 2002 and 2007.

80 to describe postoperative outcomes of total gastrectomy at our institution for patients with heredit

81 ajority of gastric cancer patients underwent gastrectomy at providing hospitals nearest to home, refl

82 Majority (67.1%) of patients underwent gastrectomy at the nearest providing hospitals.

83 ith the decision between antrectomy or total gastrectomy being empirical.

84 ric bypass or a laparoscopic vertical sleeve gastrectomy between 2007 and 2009 (n = 4088) without rev

85 urable gastric adenocarcinoma that underwent gastrectomy between 2011 and 2015, registered in the Dut

86 Patients contemplating prophylactic gastrectomy can be reassured about the long-term HRQL ou

87 nvasive treatment regimens involving radical gastrectomy, chemotherapy or radiation, or all.

88 celiac disease, inflammatory bowel diseases, gastrectomy, cholestatic liver diseases, liver transplan

89 % of 2-, 3-, transhiatal, and extended total gastrectomy cohorts, respectively (P=0.05).

90 phagectomy, pancreatectomy, partial or total gastrectomy, colectomy, lung resection, and cystectomy f

91 ectomy and pneumonectomy, 2 to 5 percent for gastrectomy, cystectomy, repair of a nonruptured abdomin

92 Laparoscopic sleeve gastrectomy did not reliably relieve or improve GERD sym

93 ients with CDH1 mutation who underwent total gastrectomy during 2005 to 2015.

94 tients who are at least 20 years postpartial gastrectomy for benign disease should be considered for

95 initial group of 233 patients who underwent gastrectomy for benign peptic ulcer disease between 1960

96 Partial gastrectomy for benign peptic ulcer disease is associate

97 le gastric banding, and most recently sleeve gastrectomy for both significant weight loss and comorbi

98 mine travel patterns for patients undergoing gastrectomy for cancer and to identify factors associate

99 ll patients undergoing curative-intent total gastrectomy for gastric adenocarcinoma between January 2

100 he optimal regional dissection extent during gastrectomy for gastric adenocarcinoma continues to be d

101 l of 4235 consecutive patients who underwent gastrectomy for gastric adenocarcinoma were identified a

102 ications with hospital costs following total gastrectomy for gastric adenocarcinoma.

103 ost important predictors of recurrence after gastrectomy for gastric adenocarcinoma.

104 date the efficacy and safety of laparoscopic gastrectomy for gastric cancer in terms of long-term sur

105 lymphadenectomy during potentially curative gastrectomy for gastric cancer.

106 bed decreased 5-year survival after curative gastrectomy for GC in the West compared with the East.

107 long-term oncologic outcomes of laparoscopic gastrectomy for patients with gastric cancer were compar

108 120 patients underwent curative-intent total gastrectomy for stage I through III gastric adenocarcino

109 e oncologic outcomes of laparoscopy-assisted gastrectomy for the treatment of gastric cancer have not

110 Patients who had a sleeve gastrectomy, gastric bypass, or duodenal switch were mor

111 ing the forestomach almost intact (glandular gastrectomy [GG]) and compared subsequent metabolic remo

112 eater in the gastric-bypass group and sleeve-gastrectomy group (-29.4+/-9.0 kg and -25.1+/-8.5 kg, re

113 roup (P<0.001), and 6.6+/-1.0% in the sleeve-gastrectomy group (P=0.003).

114 2) and 37% (18 of 49 patients) in the sleeve-gastrectomy group (P=0.008).

115 oup (P<0.001) and 24% of those in the sleeve-gastrectomy group (P=0.01).

116 stric emptying was accelerated in the sleeve gastrectomy group compared with the other 2 groups (whic

117 c-bypass group and 21.1+/-8.9% in the sleeve-gastrectomy group, as compared with a reduction of 4.2+/

118 ne observed in the gastric-bypass and sleeve-gastrectomy groups were superior to the changes seen in

119 icant larger than in the nonobese and sleeve gastrectomy groups.

120 (42.5%) who underwent an uncomplicated total gastrectomy had a mean (SD) normalized cost of MP $12330

121 alysis demonstrated that patients undergoing gastrectomy had significantly higher odds of having 15 o

122 nses in morbidly obese patients after sleeve gastrectomy has not been determined.

123 Gastric bypass and sleeve gastrectomy have a greater effect than gastric banding.

124 rgoing colectomy, cystectomy, esophagectomy, gastrectomy, hysterectomy, lung resection, pancreatectom

125 rapy plus Roux-en-Y gastric bypass or sleeve gastrectomy in 150 obese patients with uncontrolled type

126 tric cancer were comparable to those of open gastrectomy in a large-scale, multicenter, retrospective

127 remnant and can lead to completion curative gastrectomy in asymptomatic people.

128 o home, reflecting little regionalization of gastrectomy in California.

129 We performed a novel sleeve gastrectomy in rats that resects approximately 80% of th

130 CDH1 mutations are an indication for total gastrectomy in these patients.

131 o undergo Roux-en-Y gastric bypass or sleeve gastrectomy in three bariatric centers in the Netherland

132 Finally, complications after sleeve gastrectomy include postoperative leaks and strictures,

133 beyond three years was 30% in patients whose gastrectomy included en-bloc pancreatico-splenic resecti

134 taneous fistulas, reconstruction after total gastrectomy, intestinal transit after ileocecal segment

135 robot-assisted kidney transplant and sleeve gastrectomy is feasible in morbidly obese patients and a

136 advances in reconstruction techniques, total gastrectomy is still accompanied by various complication

137 Clinical trials comparing laparoscopic gastrectomy (LG) versus traditional open gastrectomy (OG

138 Operative approaches were grouped into gastrectomy (limited esophagectomy) or esophagectomy (ex

139 Laparoscopic sleeve gastrectomy (LSG) has been proposed as an effective alte

140 erm metabolic effects of laparoscopic sleeve gastrectomy (LSG) in patients with type 2 diabetes (T2DM

141 techniques to use for a laparoscopic sleeve gastrectomy (LSG) including the use of staple line reinf

142 Laparoscopic sleeve gastrectomy (LSG) increases transplant eligibility by re

143 Laparoscopic sleeve gastrectomy (LSG) is a promising procedure for adolescen

144 The prevalence of laparoscopic sleeve gastrectomy (LSG) is increasing, but data on its long-te

145 Laparoscopic sleeve gastrectomy (LSG) is performed almost as often in Europe

146 ) patients who underwent laparoscopic sleeve gastrectomy (LSG).

147 efore and 3 months after laparoscopic sleeve gastrectomy (LSG).

148 and, in particular, gastric bypass or sleeve gastrectomy may be considered as new treatment options f

149 Of the 41 patients undergoing total gastrectomy, median age was 47 years (range 20 to 71).

150 postoperative outcomes of minimally invasive gastrectomy (MIG) to open gastrectomy (OG) for cancer du

151 hagectomy (n = 5), and laparoscopic proximal gastrectomy (n = 1).

152 5 through 2003, 505 patients underwent R0/R1 gastrectomy (n = 153) or esophagectomy (n = 352) without

153 identify all 55,016 inpatients who underwent gastrectomy (n = 6434) or colectomy (n = 48,582) between

154 Roux-en-Y gastric bypass (n = 161), sleeve gastrectomy (n = 67), or laparoscopic adjustable gastric

155 , morbidly obese patients who had had sleeve gastrectomy (n = 8), and nonobese patients (n = 16).

156 her had subtotal resection (n = 29) or total gastrectomy (n = 97) for T1 gastric cancer.

157 ss, n = 162; gastric banding, n = 32; sleeve gastrectomy, n = 23), a mean excess weight loss (EWL) of

158 minimally invasive gastrectomy (MIG) to open gastrectomy (OG) for cancer during the introduction of M

159 pic gastrectomy (LG) versus traditional open gastrectomy (OG) have been planned, their surgical outco

160 bjective was to assess the effects of sleeve gastrectomy on hunger, satiation, gastric and gallbladde

161 adiological contrast swallow following total gastrectomy or distal esophagectomy cannot be recommende

162 After gastrectomy or esophagectomy, esophagogastrostomy and es

163 A high-pH environment created by surgical gastrectomy or proton pump inhibitor therapy in combinat

164 ial cells (obtained from patients undergoing gastrectomy or sleeve resection or gastric antral organo

165 stric bypass (OR 3.51, CI 2.38-5.22); sleeve gastrectomy (OR 2.46, CI 1.73-3.50).

166 c bypass (OR 3.97, CI 1.77-8.91); and sleeve gastrectomy (OR 3.50, CI 1.30-9.34).

167 , including Roux-en-Y gastric bypass, sleeve gastrectomy, or adjustable gastric banding.

168 ic banding, Roux-en-Y gastric bypass, sleeve gastrectomy, or other/unknown).

169 ined resection of the adjacent organs with a gastrectomy owing to suspicion or direct invasion of the

170 ed for colorectal procedures, esophagectomy, gastrectomy, pancreatectomy, thyroidectomy, coronary art

171 der patients (>/=65 years of age) undergoing gastrectomy, pancreaticoduodenectomy, and colectomy at a

172 Gastrectomy patients experienced an overall mortality ra

173 Sleeve gastrectomy patients showed the lowest ghrelin concentra

174 y obese and nonobese groups; however, sleeve gastrectomy patients were less hungry and more satiated

175 There were 14 955 esophagectomies and 10 671 gastrectomies performed in 141 units.

176 for gastric bypass, gastric band, or sleeve gastrectomy performed on patients with a body mass index

177 e traveled and rate of bypassing the nearest gastrectomy-performing hospitals.

178 s if they had a laparoscopic vertical sleeve gastrectomy procedure and a higher BMI at surgery, were

179 Roux-en-Y gastric bypass and vertical sleeve gastrectomy, produce significant and durable weight loss

180 istinct bariatric procedures [i.e., a sleeve gastrectomy, proximal Roux-en Y gastric bypass (RYGB), a

181 is generally to undertake prophylactic total gastrectomy (PTG).

182 patients with carcinoma underwent completion gastrectomy (R2 nodal dissection) with no evidence of ca

183 Gastrectomy remains a major operation with potential for

184 ry models, including gastric banding, sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB), modified R

185 surgery, including bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass), colorectal surge

186 Sleeve gastrectomy seems to be associated with profound changes

187 Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) account for >95% of bariatric procedure

188 objective was to study the effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGBP) on

189 Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy (SG) have been associated with a high remiss

190 Laparoscopic sleeve gastrectomy (SG) is an upcoming procedure in bariatric s

191 study was to compare the influence of sleeve gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB)

192 glucose tolerance commonly seen after sleeve gastrectomy (SG), several observations challenge this hy

193 adjustable gastric banding (AGB), or sleeve gastrectomy (SG).

194 Total gastrectomy should be considered for all CDH1 mutation c

195 hylcytosine (anti-5-methyl-C) in a series of gastrectomy specimens showed frequent loss of methylatio

196 heir primary tumor biopsies from 11 esophago-gastrectomy specimens were examined and analyzed by DESI

197 ral necrosis in 9/11 esophagectomy and 16/16 gastrectomy specimens.

198 cohorts, 5 retrospective cohorts) and sleeve gastrectomy studies (2 retrospective cohorts) had 95% co

199 After vertical sleeve gastrectomy, the level of BA increased [total: 1.17 +/-

200 ding to SES ranged from 1.04 (0.95-1.14) for gastrectomy to 1.45 (1.21-1.73) for pancreatectomy.

201 (n = 53); esophagoduodenostomy with proximal gastrectomy to induce hypergastrinemia and reflux of duo

202 le of imaging studies to localize tumor, and gastrectomy to manage acid output.

203 ch (n = 51); esophagoduodenostomy plus total gastrectomy to produce reflux of duodenal juice alone (n

204 ch, bariatric-specific data comparing sleeve gastrectomy to the adjustable gastric band, and the gast

205 11 of 47 patients (23%) who underwent sleeve gastrectomy (unadjusted P=0.03, adjusted P=0.07, P=0.17

206 Annual gastrectomy volumes for nearest and for destination hosp

207 diate part of the effects of vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass surgeries

208 er the beneficial effects of vertical sleeve gastrectomy (VSG) on plasma lipid levels are weight inde

209 Vertical sleeve gastrectomy (VSG) produces dramatic, sustained weight lo

210 Vertical sleeve gastrectomy (VSG) produces sustainable weight loss, remi

211 -Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) reduce weight and improve glucose meta

212 -Y-Gastric Bypass (RYGB) and Vertical Sleeve Gastrectomy (VSG) surgery and that these changes would i

213 his hypothesis, we performed vertical sleeve gastrectomy (VSG), a surgery with clinical efficacy very

214 iatric procedures, including vertical sleeve gastrectomy (VSG), and has been widely hypothesized to c

215 surgical procedures, such as vertical sleeve gastrectomy (VSG), are at present the most effective the

216 n-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG), are the most effective approaches to

217 diabetes mellitus undergoing vertical sleeve gastrectomy was also recruited (n = 12) as a comparison.

218 n of East Asian origin with a previous total gastrectomy was evaluated for living donor kidney transp

219 atients have durable weight loss after total gastrectomy, weights stabilize at about 6 to 12 months p

220 All partial gastrectomies were performed using a 50F bougie.

221 Histological slides from 124 primary gastrectomies were reviewed and their pathological repor

222 18,043 gastric cancer patients who underwent gastrectomy were identified from the US Surveillance, Ep

223 reast carcinoma underwent prophylactic total gastrectomy which revealed multifocal intramucosal signe

224 mplication rates of patients who underwent a gastrectomy with a combined resection of the involved or

225 lenectomy or pancreaticosplenectomy, and yet gastrectomy with additional organ resection is needed to

226 Long-term survival following gastrectomy with additional organ resection is possible.

227 t important predictors of survival following gastrectomy with additional organ resection, and a R0 re

228 rectomy alone and 268 patients who underwent gastrectomy with another organ resection.

229 Subsequently, they each underwent total gastrectomy with D-2 node dissection and Roux-en-Y esoph

230 The longitudinal gastrectomy with duodenal switch is a safe and effective

231 e decision between endoscopic mucosectomy or gastrectomy with lymphadenectomy for early gastric cance

232 The overall 5-year survival rate for the gastrectomy with organ resection group (32%, median 32 m

233 Pathologic factors revealed that the gastrectomy with organ resection group had significantly

234 He underwent a subtotal gastrectomy with Roux-en-Y gastrojejunostomy along with

235 Gastrectomy with splenectomy and other organ resections

236 disadvantages to patients who have undergone gastrectomy with splenectomy or pancreaticosplenectomy,